Molecular Partners (MOLN) reports H1 2026 results; MP0712 advances dose
Molecular Partners reports H1 2026 financial results and corporate highlights, including DLL3 radiotherapy MP0712 advancing to a higher dose level in its Phase 1/2a study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.